CN112641720A - 硫辛酸胆碱酯组合物及使用方法 - Google Patents

硫辛酸胆碱酯组合物及使用方法 Download PDF

Info

Publication number
CN112641720A
CN112641720A CN202011555416.1A CN202011555416A CN112641720A CN 112641720 A CN112641720 A CN 112641720A CN 202011555416 A CN202011555416 A CN 202011555416A CN 112641720 A CN112641720 A CN 112641720A
Authority
CN
China
Prior art keywords
aqueous
composition
lipoic acid
certain embodiments
choline ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011555416.1A
Other languages
English (en)
Chinese (zh)
Inventor
威廉·H·加纳
玛格利特·H·加纳
威廉·R·伯恩斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN112641720A publication Critical patent/CN112641720A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202011555416.1A 2014-03-03 2015-03-03 硫辛酸胆碱酯组合物及使用方法 Pending CN112641720A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461947378P 2014-03-03 2014-03-03
US61/947,378 2014-03-03
CN201580012000.6A CN106455563A (zh) 2014-03-03 2015-03-03 硫辛酸胆碱酯组合物及使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580012000.6A Division CN106455563A (zh) 2014-03-03 2015-03-03 硫辛酸胆碱酯组合物及使用方法

Publications (1)

Publication Number Publication Date
CN112641720A true CN112641720A (zh) 2021-04-13

Family

ID=54055796

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580012000.6A Pending CN106455563A (zh) 2014-03-03 2015-03-03 硫辛酸胆碱酯组合物及使用方法
CN202011555416.1A Pending CN112641720A (zh) 2014-03-03 2015-03-03 硫辛酸胆碱酯组合物及使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201580012000.6A Pending CN106455563A (zh) 2014-03-03 2015-03-03 硫辛酸胆碱酯组合物及使用方法

Country Status (12)

Country Link
US (2) US20160354340A1 (enExample)
EP (1) EP3113613A4 (enExample)
JP (1) JP6526066B2 (enExample)
KR (1) KR20160145558A (enExample)
CN (2) CN106455563A (enExample)
AU (2) AU2015227307A1 (enExample)
BR (1) BR112016020181A8 (enExample)
CA (1) CA2941518A1 (enExample)
IL (1) IL247529B (enExample)
MX (1) MX384877B (enExample)
RU (1) RU2735790C2 (enExample)
WO (1) WO2015134510A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3352739B1 (en) * 2015-09-24 2021-10-27 Novartis AG Lipoic acid choline ester compositions and methods to generate biocompatible ophthalmic formulations
JOP20190057A1 (ar) * 2016-09-23 2019-03-24 Encore Vision Inc تركيبات استر كولين حمض الليبويك وطرق تثبيتها إلى منتجات عقار ذات صلة دوائية
US10052343B1 (en) 2017-02-03 2018-08-21 Gene Signal International Sa Sterile formulation comprising a stable phosphorothioate oligonucleotide
CN107089967A (zh) * 2017-05-12 2017-08-25 苏州富士莱医药股份有限公司 一种r‑硫辛酸胆碱酯卤化物的制备方法
CN106967044B (zh) * 2017-05-12 2019-02-22 苏州富士莱医药股份有限公司 制备r-硫辛酸胆碱酯卤化物的方法
CN109394745A (zh) * 2017-08-17 2019-03-01 博瑞生物医药（苏州）股份有限公司 一种包含左旋肉碱和β-羟基丁酸化合物的组合物
US20220151989A1 (en) * 2019-04-17 2022-05-19 Santen Pharmaceutical Co., Ltd. Lipoic acid prodrug
US20200383946A1 (en) * 2019-05-07 2020-12-10 Aciont Inc. Lipoic acid formulations
CN113387923A (zh) * 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
CN113717770B (zh) * 2020-05-25 2022-06-03 中国石油天然气股份有限公司 一种金属加工油
GB202305212D0 (en) 2023-04-06 2023-05-24 Elixa Mediscience Ltd Compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090227677A1 (en) * 2008-03-05 2009-09-10 Encore Health, Llc Low Dose Lipoic Acid Pharmaceutical Compositions and Methods
US20100317725A1 (en) * 2009-06-15 2010-12-16 Encore Health Llc Choline Esters

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB935962A (en) 1960-06-17 1963-09-04 Fujisawa Pharmaceutical Co Improvements in or relating to the production of 6.8-dithiooctanamides
US3855240A (en) 1969-04-28 1974-12-17 Exxon Research Engineering Co Sulfur containing heterocycles
US4210667A (en) 1979-04-19 1980-07-01 Pfizer Inc. Pharmaceutical preparations containing coumarin carboxylic acid derivatives
US4755528A (en) 1984-12-06 1988-07-05 Alcon Laboratories, Inc. High energy ionizing protective 2,3-diamino-1,4-butanedithiol; 4,5-diamino-1,2-dithiane; and N-acyl and N-alkyl derivatives thereof, compositions and method of use therefor
US6030950A (en) 1987-07-09 2000-02-29 Ohlenschlaeger; Gerhard Pharmaceutical therapeutic use of glutathione derivative
US5599903A (en) 1992-04-03 1997-02-04 Terrapin Technologies, Inc. Glutathione analogs and paralog panels comprising glutathione mimics
FR2638970A1 (fr) 1988-11-16 1990-05-18 Corbiere Jerome Nouvelles compositions pharmaceutiques agissant sur la presbytie et leur procede d'obtention
WO1993002639A1 (en) 1991-08-06 1993-02-18 Autogenesis Technologies, Inc. Injectable collagen-based compositions for making intraocular lens
US5466680A (en) 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
WO1993025166A1 (en) 1992-06-10 1993-12-23 Summit Technology, Inc. Correction of presbyopia by photorefractive keratectomy
WO1994001096A1 (en) 1992-07-02 1994-01-20 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
EP0649532B1 (en) 1992-07-06 1997-11-12 Biomira, Inc. Photoactivation of proteins for conjugation purposes
US5465737A (en) 1992-07-15 1995-11-14 Schachar; Ronald A. Treatment of presbyopia and other eye disorders
US5354331A (en) 1992-07-15 1994-10-11 Schachar Ronald A Treatment of presbyopia and other eye disorders
WO1994003129A1 (en) 1992-08-07 1994-02-17 Keravision Inc. Hybrid intrastromal corneal ring
DE4345199C2 (de) 1993-05-22 1995-10-12 Asta Medica Ag Verwendung von Dihydroliponsäure zur Unterdrückung von Unverträglichkeitsreaktionen im Grenzbereich von Implantaten mit lebendem Körpergewebe
US5395356A (en) 1993-06-04 1995-03-07 Summit Technology, Inc. Correction of presbyopia by photorefractive keratectomy
US5527774A (en) 1993-07-12 1996-06-18 Girard; Louis J. Dislocation of cataractous lens by enzymatic zonulolysis
US5665770A (en) 1993-11-05 1997-09-09 Gakko Hojin Kinki Daigaku Method for treatment of cataract with radical scavenger
CA2185699A1 (en) 1994-04-04 1995-10-12 William R. Freeman Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
US6063116A (en) 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing
US6743779B1 (en) 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5624955A (en) 1995-05-03 1997-04-29 Regents Of The University Of Minnesota Compounds that enhance the concentration of glutathione in tissues
US5686450A (en) 1995-06-07 1997-11-11 Alcon Laboratories, Inc. Use of N,N'-bis(mercaptoacetyl) hydrazine derivatives as anticataract agents
US6007510A (en) 1996-10-25 1999-12-28 Anamed, Inc. Implantable devices and methods for controlling the flow of fluids within the body
US5817630A (en) 1997-03-18 1998-10-06 Austin Nutriceutical Corporation Glutathione antioxidant eye drops
AU728488B2 (en) 1997-04-02 2001-01-11 Sankyo Company Limited Dithiolan derivatives, their preparation and their therapeutic effect
US5843184A (en) 1998-01-26 1998-12-01 Cionni; Robert J. Endocapsular tension ring and method of implanting same
US6153647A (en) 1998-11-12 2000-11-28 My-Tech, Inc. Method for augmenting the inotropic effects of β-adrenergic agonists using pyruvate therapy
US6472541B2 (en) 1998-11-20 2002-10-29 The Regents Of The University Of California Protecting groups with increased photosensitivities
WO2000032235A1 (de) 1998-11-26 2000-06-08 Pentapharm Ag Transportsystemkonjugate
US6288106B1 (en) 1999-05-25 2001-09-11 Chronorx, Llc Processes for the synthesis and use of various α-lipoic acid complexes
AU5601300A (en) 1999-06-09 2000-12-28 Department Of The Army, U.S. Government Method and compositions for treating and preventing retinal damage
JP4476435B2 (ja) * 1999-07-22 2010-06-09 株式会社細川洋行 仕切部材、複室輸液容器および薬剤入り複室輸液容器の製造方法
US6890896B1 (en) 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6387945B2 (en) 2000-04-11 2002-05-14 The Regents Of The University Of California Lipoic acid analogs
EP1303215A1 (en) 2000-07-10 2003-04-23 Koninklijke Philips Electronics N.V. Geometry matching for imaging medical apparatus
US6906210B2 (en) 2000-08-02 2005-06-14 Basf Aktiengesellschaft Method for producing lipoic acid and dihydrolipoic acid
US7935332B2 (en) 2000-08-16 2011-05-03 Encore Health, Llc Presbyopia treatment by lens alteration
US8697109B2 (en) 2000-08-16 2014-04-15 Encore Health, Llc Caged mercaptan and seleno-mercaptan compounds and methods of using them
AU2001283386A1 (en) 2000-08-16 2002-02-25 Refocus, Llc. Presbyopia treatment by lens alteration
US7914815B2 (en) 2000-08-16 2011-03-29 Encore Health, Llc Method for delivery of pharmaceuticals for treating or preventing presbyopia
US6923955B2 (en) 2000-08-16 2005-08-02 Newlens, Llc Presbyopia treatment by lens alteration
US8647612B2 (en) 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
US20050112113A1 (en) 2000-08-16 2005-05-26 Till Jonathan S. Presbyopia treatment by lens alteration
DE10045059A1 (de) 2000-09-12 2002-03-21 Basf Ag Therapeutische Kombination von Liponsäure und Konjuensäuren zur Behandlung diabetischer Störungen
US6273092B1 (en) 2000-09-22 2001-08-14 Gerard M. Nolan Methods for treating various eye disorders
US6703039B2 (en) 2000-12-06 2004-03-09 Bausch & Lomb Incorporated Reversible gelling system for ocular drug delivery
EP1808158A3 (en) 2001-01-19 2008-06-18 Newlens, LLC Presbyopia treatment by lens alteration
ATE446949T1 (de) 2001-03-19 2009-11-15 Senju Pharma Co Neues a-liponsäurederivat und dessen verwendung
EP1521735A2 (en) 2001-05-25 2005-04-13 Ceremedix, Inc Single amino acid based compounds for counteracting effects of reactive oxygen species and free radicals
FR2832637B1 (fr) 2001-06-07 2004-07-30 Lefaix Marie Therese Droy Utilisation d'un antioxydant pour la fabrication d'un medicament destine au traitement des affections oculaires de surface
ITMI20011232A1 (it) 2001-06-12 2002-12-12 St Microelectronics Srl Metodo di riprogrammazione successiva ad una operazione di cancellazione di una matrice di celle di memoria non volatile, in particolare di
AU2002254546A1 (en) 2002-04-03 2003-10-20 Mitchell A. Avery Lipoic acid analogs useful as provitamins and antioxidants
US20050137124A1 (en) 2002-08-09 2005-06-23 Vitreo-Retinal Technologies, Inc. A California Corporation Agents for intravitreal administration to treat or prevent disorders of the eye
WO2004024139A1 (ja) 2002-09-13 2004-03-25 Oga Research, Incorporated メラニン消去剤
US7795203B2 (en) * 2002-09-30 2010-09-14 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
US20060177430A1 (en) 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US7941211B2 (en) 2003-11-17 2011-05-10 Zeavision, Llc. Preloading with macular pigment to improve photodynamic treatment of retinal vascular disorders
US7585846B2 (en) 2003-11-25 2009-09-08 University Of Rochester Compounds for delivering amino acids or peptides with antioxidant activity into mitochondria and use thereof
US7718697B2 (en) 2003-12-17 2010-05-18 Alcon, Inc. Method for treating glaucoma comprising administering α-lipoic acid
GB0404693D0 (en) 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
FR2869531B1 (fr) 2004-04-30 2006-07-14 Optis France Sa Sa Dispositif de iontophorese oculaire diminuant les irritations
US7264279B2 (en) 2004-07-08 2007-09-04 Fab-Tech, Inc. Segmented conduit having a monolithic lining
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US20060188492A1 (en) 2005-01-13 2006-08-24 Chronorx Llc, An Alaska Limited Liability Company Topical management of ocular and periocular conditions
US20060275278A1 (en) * 2005-06-02 2006-12-07 Choy Camus K M Method and ophthalmic formulation for eye protection or treatment
AU2006270035A1 (en) 2005-07-15 2007-01-25 Chakshu Research Inc. Formulation and method for administration of ophthalmologically active agents
US20070055070A1 (en) 2005-09-07 2007-03-08 Lawrence Lowell J Novel esters of lipoic acid
US20070207116A1 (en) * 2006-03-01 2007-09-06 Brown David C Antioxidant compositions for the eye
JP2009541220A (ja) 2006-06-16 2009-11-26 インディジーン ファーマシューティカルズ インコーポレイテッド 糖尿病性高血糖および糖尿病合併症の制御のための抗糖尿病薬としてのメトホルミンｒ−（＋）リポエート
WO2008067403A2 (en) 2006-11-28 2008-06-05 Encore Health Llc Presbyopia treatment by lens alteration
WO2008068350A1 (de) * 2006-12-08 2008-06-12 Sachtleben Chemie Gmbh Titanhaltige formkörper
DE102006062599B4 (de) 2006-12-29 2018-03-08 Endress + Hauser Gmbh + Co. Kg Opto-elektronische Vorrichtung zur Übertragung eines elektrischen Signals und deren Verwendung
EP3539560A1 (en) 2007-02-22 2019-09-18 Children's Hospital & Research Center at Oakland Fatty acid formulations and methods of use thereof
WO2008106640A1 (en) 2007-03-01 2008-09-04 Cedars-Sinai Medical Center Antioxidant polymers containing [1,2]-dithiolane moieties and uses thereof
UA86441C2 (ru) 2007-03-30 2009-04-27 Акционерное Общество Открытого Типа "Галичфарм" (2-гидроксиэтил)триметиламмония тиоктат (холина тиоктат), имеющий гепатопротекторное, гипоаммониемическое и детоксицирующее действие, способ его получения, фармацевтическая композиция на его основе
PL391002A1 (pl) * 2007-08-09 2010-10-25 Senju Pharmaceutical Co, Ltd Dwuskładnikowe krople do oczu zawierające pirenoksynę
WO2009111635A2 (en) 2008-03-05 2009-09-11 Encore Health, Llc Dithiol compounds, derivatives, and uses therefor
EP2442647B1 (en) 2009-06-15 2016-03-16 Encore Health LLC Dithiol compounds, derivatives, and uses therefor
DE102010009475B4 (de) * 2010-02-26 2011-11-24 F. Holzer Gmbh Verfahren zur Herstellung eines dosierbaren applikationsfertigen Präparates
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
CA2819988C (en) * 2011-01-04 2019-11-12 Novaliq Gmbh O/w-emulsions comprising semifluorinated alkanes
CA2862974C (en) * 2012-01-23 2021-11-16 Novaliq Gmbh Stabilised protein compositions based on semifluorinated alkanes
EP3281634A1 (en) * 2012-02-22 2018-02-14 Stealth Peptides International, Inc. Method and compositions for preventing or treating ophthalmic conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090227677A1 (en) * 2008-03-05 2009-09-10 Encore Health, Llc Low Dose Lipoic Acid Pharmaceutical Compositions and Methods
US20100317725A1 (en) * 2009-06-15 2010-12-16 Encore Health Llc Choline Esters

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
张汝华等: "《工业药剂学》", 中国医药科技出版社, pages: 55 *

Also Published As

Publication number Publication date
RU2016137784A3 (enExample) 2018-10-18
CA2941518A1 (en) 2015-09-11
US20200281891A1 (en) 2020-09-10
AU2015227307A1 (en) 2016-10-13
RU2735790C2 (ru) 2020-11-09
JP6526066B2 (ja) 2019-06-05
MX2016011290A (es) 2017-04-27
EP3113613A1 (en) 2017-01-11
US11426381B2 (en) 2022-08-30
MX384877B (es) 2025-03-14
AU2019240641B2 (en) 2020-10-29
RU2016137784A (ru) 2018-04-03
KR20160145558A (ko) 2016-12-20
CN106455563A (zh) 2017-02-22
IL247529A0 (en) 2016-11-30
WO2015134510A1 (en) 2015-09-11
BR112016020181A8 (pt) 2021-06-29
BR112016020181A2 (pt) 2017-08-15
IL247529B (en) 2020-10-29
AU2019240641A1 (en) 2019-10-24
EP3113613A4 (en) 2019-03-13
JP2017511816A (ja) 2017-04-27
US20160354340A1 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
US11426381B2 (en) Lipoic acid choline ester compositions and methods of use
ES2524706T3 (es) Ésteres de colina
ES3007759T3 (en) Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
US8389014B2 (en) Gel useful for the delivery of ophthalmic drugs
US20220096434A1 (en) Lipoic acid choline ester compositions and methods to generate biocompatible ophthalmic formulations
US11957646B2 (en) Methods and compositions of stable phenylephrine formulations
KR102663319B1 (ko) 안구 장애를 치료하기 위한 옥시메타졸린 조성물 및 방법
US20090169629A1 (en) Micellar compositions with ophthalmic applications
ES3008008T3 (en) Use of high molecular weight hyaluronic acid as ocular transporting vehicle
KR20190065304A (ko) 리포산 콜린 에스테르 조성물 및 약제학적으로 관련된 약물 생성물 내로 안정화시키는 방법
US20090170944A1 (en) Ophthalmic micellar compositions with enhanced stability
US20250281434A1 (en) Ophthalmic pharmaceutical compositions and uses thereof
AU2021288467B2 (en) Treatment of cystinosis
TWI896143B (zh) 一種有效延緩及治療近視的藥物組合物
RU2820596C2 (ru) Композиции оксиметазолина и способы для лечения офтальмологических расстройств
Robb et al. Preclinical Evaluation of a Pilocarpine–(R)-Lipoic Acid Eye Drop for Presbyopia
EP2077104A1 (en) Micellar compositions with ophtalmic applications
EP2077105A1 (en) Ophthalmic Micellar Compositions with Enhanced Stability
ESTERS PATENT APPLICATION
CN104873519A (zh) 一种曲伏前列素眼用组合物及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210413